TELIX PHARMACEUTICALS ORD
Weekly Wrap: Strong Week Despite Late Fade
ASX up 4.4% for the week; strongest since Oct 2022, despite Friday fade. Magellan-Barrenjoey merger approved; Telix jumps on US regulator nod; Iran talks ahead.
Telix Pharmaceuticals to acquire Canadian isotope innovator ARTMS in $125.9m deal
Australian biopharmaceutical company Telix Pharmaceuticals (ASX: TLX) is set to acquire Canadian radioisotope technology firm ARTMS Inc in a $125.9 million deal designed to boost its supply chain and production capacity. The deal will include ARTMS’ advanced cyclotron-based isotope production platform, a manufacturing plant and a stockpile of ultra-pure rare metals required for consumable target […]
Medibank suffers cyberattack, Telix Pharma expands GE Healthcare partnership and APA Group to acquire Basslink
Health insurance provider Medibank Private’s (ASX: MPL) shares are down this week after the company revealed it suffered a major cyber security incident. Despite the concern, the provider urged there was no evidence of customers’ data being accessed and has since returned to business as usual. Medibank has a large database, covering more than 3.7 […]
Telix withdraws Europe marketing application, AGL to close power station early and BHP prioritises Peru exploration
Telix Pharmaceuticals (ASX: TLX) has announced it has withdrawn its application to market the company’s lead prostate cancer imaging product, Illuccix, in Europe. The Danish Medicines Agency asked for additional chemistry, manufacturing and control data from Telix, but the Australian company said the requests could not be delivered within the prescribed review timeframe. Telix group […]